TAK

Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.

Wall Street analysts forecast TAK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TAK is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Takeda Pharmaceutical Co Ltd revenue for the last quarter amounts to 1.11T USD, decreased -5.38 % YoY.

Takeda Pharmaceutical Co Ltd. EPS for the last quarter amounts to -7.48 USD, decreased -113.08 % YoY.

Takeda Pharmaceutical Co Ltd (TAK) has 47455 emplpoyees as of December 15 2025.

Today TAK has the market capitalization of 46.47B USD.